See more : Move About Group AB (publ) (MOV.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Canopy Growth Corporation (CGC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Canopy Growth Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- PT Paninvest Tbk (PNIN.JK) Income Statement Analysis – Financial Results
- Hangzhou Weiguang Electronic Co.,Ltd. (002801.SZ) Income Statement Analysis – Financial Results
- NovoCure Limited (NVCR) Income Statement Analysis – Financial Results
- U.S. Energy Initiatives Corporation Inc. (USEI) Income Statement Analysis – Financial Results
- Endo International plc (0Y5F.L) Income Statement Analysis – Financial Results
Canopy Growth Corporation (CGC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.canopygrowth.com
About Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 297.15M | 402.90M | 520.33M | 546.65M | 398.77M | 226.34M | 77.95M | 39.90M | 12.70M | 1.15M | 0.00 | 4.14K | 0.00 | 4.49K | 549.00 |
| Cost of Revenue | 216.26M | 507.04M | 713.38M | 479.69M | 430.46M | 137.41M | 3.76M | 2.26M | -6.29M | 731.31K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 80.88M | -104.14M | -193.05M | 66.96M | -31.68M | 88.93M | 74.19M | 37.63M | 18.99M | 414.35K | 0.00 | 4.14K | 0.00 | 4.49K | 549.00 |
| Gross Profit Ratio | 27.22% | -25.85% | -37.10% | 12.25% | -7.95% | 39.29% | 95.18% | 94.33% | 149.51% | 36.17% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 4.61M | 21.72M | 32.34M | 57.58M | 61.81M | 15.24M | 1.45M | 810.00K | 721.00K | 159.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 99.83M | 487.41M | 520.28M | 666.54M | 624.91M | 451.44M | 92.93M | 25.59M | 11.67M | 6.00M | 739.94K | 68.75K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 76.15M | 243.45M | 239.28M | 194.40M | 242.83M | 154.39M | 38.20M | 12.96M | 5.65M | 1.99M | 191.72K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 175.98M | 487.41M | 520.28M | 666.54M | 867.74M | 605.83M | 131.13M | 38.55M | 17.33M | 7.99M | 931.66K | 68.75K | 26.16K | 28.56K | 27.47K |
| Other Expenses | 129.01M | -21.72M | -32.34M | -57.58M | 63.62M | 21.51M | 20.49M | -585.00K | 2.26M | -966.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 309.60M | 487.41M | 520.28M | 666.54M | 993.17M | 642.58M | 153.07M | 45.43M | 20.30M | 8.15M | 931.66K | 68.75K | 26.16K | 28.56K | 27.47K |
| Cost & Expenses | 525.86M | 994.46M | 1.23B | 1.15B | 1.42B | 779.99M | 156.82M | 47.69M | 14.02M | 8.88M | 931.66K | 68.75K | 26.16K | 28.56K | 27.47K |
| Interest Income | 16.24M | 24.28M | 6.60M | 21.37M | 66.33M | 49.31M | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.76K | 4.49K | 549.00 |
| Interest Expense | 105.35M | 126.16M | 103.94M | 8.46M | 6.72M | 18.42M | 784.00K | 66.00K | 140.00K | 65.82K | 1.27K | 0.00 | 4.76K | 4.49K | 0.00 |
| Depreciation & Amortization | 53.18M | 80.03M | 114.42M | 127.12M | 125.01M | 46.92M | 20.49M | 6.06M | 2.26M | 362.90K | 4.19K | 0.00 | -4.76K | -4.49K | 0.00 |
| EBITDA | -312.83M | -2.88B | -121.15M | -1.50B | -1.31B | -631.83M | -29.80M | -692.00K | 938.00K | -6.96M | -925.99K | -64.61K | -26.16K | -24.07K | -26.92K |
| EBITDA Ratio | -105.28% | 434.27% | -44.12% | 31.36% | -340.35% | -213.54% | -118.58% | 17.12% | 20.27% | -618.02% | 0.00% | -1,559.07% | 0.00% | -536.27% | -4,903.10% |
| Operating Income | -228.71M | 1.67B | -1.08B | 44.30M | -1.67B | -553.65M | -78.88M | -15.22M | -2.75M | -7.74M | -931.66K | -64.61K | -21.39K | -19.58K | -26.92K |
| Operating Income Ratio | -76.97% | 413.30% | -208.08% | 8.10% | -418.53% | -244.61% | -101.19% | -38.14% | -21.65% | -675.34% | 0.00% | -1,559.07% | 0.00% | -436.27% | -4,903.10% |
| Total Other Income/Expenses | -242.64M | -455.64M | 750.94M | -440.51M | 159.91M | -59.71M | 68.53M | 3.81M | -621.00K | -912.37K | -1.27K | 0.00 | 0.00 | 0.00 | 26.92K |
| Income Before Tax | -471.36M | -3.31B | -329.43M | -1.68B | -1.51B | -657.78M | -52.54M | -17.06M | -3.37M | -8.93M | -932.93K | -64.61K | -21.39K | 0.00 | 0.00 |
| Income Before Tax Ratio | -158.63% | -822.61% | -63.31% | -308.05% | -378.43% | -290.61% | -67.41% | -42.76% | -26.54% | -779.58% | 0.00% | -1,559.07% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 12.33M | -4.77M | -8.95M | -13.14M | -121.61M | 12.32M | 1.59M | -401.00K | 126.00K | 1.42M | 2.75K | 0.00 | -4.76K | -4.49K | 26.92K |
| Net Income | -657.27M | -3.31B | -320.49M | -1.67B | -1.39B | -670.09M | -54.13M | -16.61M | -3.50M | -8.93M | -932.93K | -64.61K | -21.39K | -24.07K | -26.92K |
| Net Income Ratio | -221.19% | -821.42% | -61.59% | -305.65% | -347.93% | -296.06% | -69.45% | -41.63% | -27.53% | -779.58% | 0.00% | -1,559.07% | 0.00% | -536.27% | -4,903.10% |
| EPS | -6.47 | -71.37 | -8.19 | -44.96 | -39.86 | -1.99 | -0.31 | -0.14 | -0.05 | -0.30 | -15.77 | -0.06 | -0.02 | -0.02 | -0.08 |
| EPS Diluted | -8.79 | -71.37 | -8.19 | -44.96 | -39.86 | -1.99 | -0.31 | -0.14 | -0.05 | -0.30 | -15.77 | -0.06 | -0.02 | -0.02 | -0.08 |
| Weighted Avg Shares Out | 101.63M | 46.37M | 39.13M | 37.17M | 34.80M | 337.51M | 177.30M | 118.99M | 77.02M | 29.95M | 59.16K | 1.00M | 1.00M | 1.00M | 320.24K |
| Weighted Avg Shares Out (Dil) | 74.79M | 46.37M | 39.13M | 37.17M | 34.80M | 337.51M | 177.30M | 118.99M | 77.02M | 29.95M | 59.16K | 1.00M | 1.00M | 1.00M | 320.24K |
Here's why Tilray Brands, Canopy Growth, Curaleaf stocks have crashed
Cannabis stocks have crashed hard this year as concerns about the industry continued. The AdvisorShares Pure US Cannabis ETF (MSOS) stock has plunged by almost 14% this year and is down by over 46% from its highest point this year.
Must-buy stocks if Kamala Harris wins the U.S. election
The financial markets are closely monitoring the upcoming U.S. election, as the outcome will likely have significant implications for the broader economy. Both candidates, Donald Trump and Kamala Harris, have outlined their policies, which are expected to influence investment strategies.
Cannabis Stocks Slide as DEA Sets Post-Election Marijuana Hearing in December
Cannabis stocks slumped Tuesday after the Drug Enforcement Administration (DEA) announced a hearing that could reclassify marijuana as a less harmful, Schedule III drug won't come until Dec. 2—after the 2024 presidential election.
3 Weed Stocks Sinking on Reclassification Hearing Update
The U.S. Drug Enforcement Administration (DEA) today announced a proposal hearing on the reclassification of marijuana as a less restricted Schedule III drug will happen on Dec. 2, after the presidential election.
Prediction: Aurora Cannabis Will Be Worth More Than Canopy Growth in 5 Years
Aurora Cannabis and Canopy Growth have been leading companies within the cannabis industry for years. Both businesses have struggled, however, and have been working on improving their financials.
Top Canadian Cannabis Stocks to Watch Now: High-Growth Opportunities in 2024
The Canadian cannabis market continues to play a pivotal role in the North American cannabis industry. As US cannabis laws evolve, Canadian companies are well-positioned to capitalize on this growth. The US cannabis industry is expected to reach $45.9 billion...
3 Of Today's Top Canadian Marijuana Stock Picks For Investors
What's next for marijuana stock investors as the sector's recent rise in trading has people talking. Recently there has been an increase in trading that allowed some investors to take profits. Yet in true cannabis fashion, this rise in trading...
Canopy Growth CEO to step down
Cannabis firm Canopy Growth said on Friday its CEO, David Klein, will retire at the end of the company's current fiscal year ending March 31, 2025.
Canopy Growth Announces CEO Succession Plan
David Klein, CEO to retire at the end of the Company's fiscal year Board of Directors expresses continued confidence in the Company's strategic direction and leadership team A comprehensive CEO selection process has been initiated to identify a successor This...
Canopy Growth Corporation (CGC) is Attracting Investor Attention: Here is What You Should Know
Canopy Growth (CGC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Source: https://incomestatements.info
Category: Stock Reports